A significant breakthrough in 2025 could be the escalating utilization of repurposed medicines—prescription drugs originally developed for non-cancer ailments but now demonstrating guarantee in oncology. Medicine like ivermectin, mebendazole, and fenbendazole, historically applied as antiparasitic brokers, are being studied for their anticancer H